Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Association Between Heart Rate and Reversibility of the Symptom, Refractoriness to Palliative Treatment, and Survival in Dyspneic Cancer Patients.

Mori I, Maeda I, Morita T, Inoue S, Ikenaga M, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Watanabe H.

J Pain Symptom Manage. 2020 Feb 21. pii: S0885-3924(20)30097-X. doi: 10.1016/j.jpainsymman.2020.02.011. [Epub ahead of print]

PMID:
32088356
2.

Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H.

BMJ Open. 2019 Dec 2;9(12):e033131. doi: 10.1136/bmjopen-2019-033131.

3.

Formation of silicate nanoscrolls through solvothermal treatment of layered octosilicate intercalated with organoammonium ions.

Asakura Y, Sugihara M, Hirohashi T, Torimoto A, Matsumoto T, Koike M, Kuroda Y, Wada H, Shimojima A, Kuroda K.

Nanoscale. 2019 Jul 11;11(27):12924-12931. doi: 10.1039/c9nr01651a.

PMID:
31250866
4.

A combination of routine laboratory findings and vital signs can predict survival of advanced cancer patients without physician evaluation: a fractional polynomial model.

Hamano J, Takeuchi A, Yamaguchi T, Baba M, Imai K, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Nagaoka H, Mori M, Tei Y, Hiramoto S, Morita T.

Eur J Cancer. 2018 Dec;105:50-60. doi: 10.1016/j.ejca.2018.09.037. Epub 2018 Nov 2.

PMID:
30391780
5.

A prospective, multicenter cohort study to validate a simple performance status-based survival prediction system for oncologists.

Yamada T, Morita T, Maeda I, Inoue S, Ikenaga M, Matsumoto Y, Baba M, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Ono S, Ozawa T, Yamamoto R, Shishido H, Yamamoto N.

Cancer. 2017 Apr 15;123(8):1442-1452. doi: 10.1002/cncr.30484. Epub 2016 Dec 7.

6.

A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors.

Doi T, Lee KH, Kim TM, Ohtsu A, Kim TY, Ikeda M, Yoh K, Gallo Stampino C, Hirohashi T, Suzuki A, Fujii Y, Andrew Williams J, Bang YJ.

Cancer Med. 2016 Jul;5(7):1454-63. doi: 10.1002/cam4.724. Epub 2016 Apr 14.

7.

Clinical Implications of C-Reactive Protein as a Prognostic Marker in Advanced Cancer Patients in Palliative Care Settings.

Amano K, Maeda I, Morita T, Miura T, Inoue S, Ikenaga M, Matsumoto Y, Baba M, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Kinoshita H.

J Pain Symptom Manage. 2016 May;51(5):860-7. doi: 10.1016/j.jpainsymman.2015.11.025. Epub 2016 Jan 28.

8.

Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study.

Maeda I, Morita T, Yamaguchi T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Tei Y, Kikuchi A, Baba M, Kinoshita H.

Lancet Oncol. 2016 Jan;17(1):115-22. doi: 10.1016/S1470-2045(15)00401-5. Epub 2015 Nov 29.

PMID:
26610854
9.

Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model.

Baba M, Maeda I, Morita T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Tei Y, Hiramoto S, Suga A, Kinoshita H.

Eur J Cancer. 2015 Aug;51(12):1618-29. doi: 10.1016/j.ejca.2015.04.025. Epub 2015 Jun 11.

PMID:
26074396
10.

Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study.

Hamano J, Morita T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Yamamoto N, Shimizu M, Sasara T, Kinoshita H.

Oncologist. 2015 Jul;20(7):839-44. doi: 10.1634/theoncologist.2015-0015. Epub 2015 Jun 8.

11.

Depletion of T regulatory cells promotes natural killer cell-mediated cardiac allograft vasculopathy.

Hirohashi T, Chase CM, DellaPelle P, Sebastian D, Farkesh E, Colvin RB, Russell PS, Alessandrini A, Madsen JC.

Transplantation. 2014 Oct 27;98(8):828-34. doi: 10.1097/TP.0000000000000329.

12.

Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.

Hirohashi T, Igarashi K, Abe M, Maeda M, Hino O.

Mol Clin Oncol. 2014 Jan;2(1):26-30. Epub 2013 Oct 2.

13.

Role of complement and NK cells in antibody mediated rejection.

Akiyoshi T, Hirohashi T, Alessandrini A, Chase CM, Farkash EA, Neal Smith R, Madsen JC, Russell PS, Colvin RB.

Hum Immunol. 2012 Dec;73(12):1226-32. doi: 10.1016/j.humimm.2012.07.330. Epub 2012 Jul 28. Review.

14.

Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.

Yoshino T, Yamazaki K, Hamaguchi T, Shimada Y, Kato K, Yasui H, Boku N, Lechuga MJ, Hirohashi T, Shibata A, Hashigaki S, Li Y, Ohtsu A.

Anticancer Res. 2012 Mar;32(3):973-9.

PMID:
22399619
15.

A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB.

Am J Transplant. 2012 Feb;12(2):313-21. doi: 10.1111/j.1600-6143.2011.03836.x. Epub 2011 Nov 9.

16.

Coronary artery disease from isolated non-H2-determined incompatibilities in transplanted mouse hearts.

Russell PS, Chase CM, Madsen JC, Hirohashi T, Cornell LD, Sproule TJ, Colvin RB, Roopenian DC.

Transplantation. 2011 Apr 27;91(8):847-52. doi: 10.1097/TP.0b013e3182122f82.

17.

Emerging role of B cells in chronic allograft dysfunction.

Colvin RB, Hirohashi T, Farris AB, Minnei F, Collins AB, Smith RN.

Kidney Int Suppl. 2010 Dec;(119):S13-7. doi: 10.1038/ki.2010.436. Review.

18.

An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance.

Zhao G, Moore DJ, Lee KM, Kim JI, Duff PE, O'Connor MR, Hirohashi T, Lei J, Yang M, Markmann JF, Deng S.

Am J Transplant. 2010 Apr;10(4):796-801. doi: 10.1111/j.1600-6143.2010.03027.x. Epub 2010 Feb 25.

19.

Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice.

Hirohashi T, Uehara S, Chase CM, DellaPelle P, Madsen JC, Russell PS, Colvin RB.

Am J Transplant. 2010 Mar;10(3):510-7. doi: 10.1111/j.1600-6143.2009.02958.x. Epub 2010 Jan 5.

20.

Viral infection induces de novo lesions of coronary allograft vasculopathy through a natural killer cell-dependent pathway.

Graham JA, Wilkinson RA, Hirohashi T, Chase CM, Colvin RB, Madsen JC, Fishman JA, Russell PS.

Am J Transplant. 2009 Nov;9(11):2479-84. doi: 10.1111/j.1600-6143.2009.02801.x.

21.

Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.

Sakamoto T, Moriya M, Tsuge H, Takahashi T, Haga Y, Nonoshita K, Okamoto O, Takahashi H, Sakuraba A, Hirohashi T, Shibata T, Kanno T, Ito J, Iwaasa H, Gomori A, Ishihara A, Fukuroda T, Kanatani A, Fukami T.

Bioorg Med Chem. 2009 Jul 15;17(14):5015-26. doi: 10.1016/j.bmc.2009.05.064. Epub 2009 Jun 2.

PMID:
19525116
22.

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

Takahashi T, Haga Y, Sakamoto T, Moriya M, Okamoto O, Nonoshita K, Shibata T, Suga T, Takahashi H, Hirohashi T, Sakuraba A, Gomori A, Iwaasa H, Ohe T, Ishihara A, Ishii Y, Kanatani A, Fukami T.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3511-6. doi: 10.1016/j.bmcl.2009.05.013. Epub 2009 May 9.

PMID:
19464889
23.

(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.

Sato N, Jitsuoka M, Shibata T, Hirohashi T, Nonoshita K, Moriya M, Haga Y, Sakuraba A, Ando M, Ohe T, Iwaasa H, Gomori A, Ishihara A, Kanatani A, Fukami T.

J Med Chem. 2008 Aug 14;51(15):4765-70. doi: 10.1021/jm8003587. Epub 2008 Jul 19.

PMID:
18637668
24.

Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.

Takahashi T, Sakuraba A, Hirohashi T, Shibata T, Hirose M, Haga Y, Nonoshita K, Kanno T, Ito J, Iwaasa H, Kanatani A, Fukami T, Sato N.

Bioorg Med Chem. 2006 Nov 15;14(22):7501-11. Epub 2006 Aug 17.

PMID:
16919461
25.

Chronic intracerebroventricular administration of relaxin-3 increases body weight in rats.

Hida T, Takahashi E, Shikata K, Hirohashi T, Sawai T, Seiki T, Tanaka H, Kawai T, Ito O, Arai T, Yokoi A, Hirakawa T, Ogura H, Nagasu T, Miyamoto N, Kuromitsu J.

J Recept Signal Transduct Res. 2006;26(3):147-58.

PMID:
16777712
26.

[Study of the echocardiographic diagnosis of acute pulmonary thromboembolism and risk factors for venous thromboembolism].

Hirohashi T, Yoshinaga K, Sakurai T, Kanai M, Shimizu K, Sugiyama Y, Noike H, Ohsawa H, Sakuragawa H, Tokuhiro K, Takahashi O, Tomaru T.

J Cardiol. 2006 Feb;47(2):63-71. Japanese.

PMID:
16515356
27.

Characterization of the preprotein translocon at the outer envelope membrane of chloroplasts by blue native PAGE.

Kikuchi S, Hirohashi T, Nakai M.

Plant Cell Physiol. 2006 Mar;47(3):363-71. Epub 2006 Jan 13.

PMID:
16415065
28.

Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice.

Sagane K, Hayakawa K, Kai J, Hirohashi T, Takahashi E, Miyamoto N, Ino M, Oki T, Yamazaki K, Nagasu T.

BMC Neurosci. 2005 May 6;6:33.

29.

Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists.

Sato N, Shibata T, Jitsuoka M, Ohno T, Takahashi T, Hirohashi T, Kanno T, Iwaasa H, Kanatani A, Fukami T.

Bioorg Med Chem Lett. 2004 Apr 5;14(7):1761-4.

PMID:
15026066
30.

Cytoplasmic expression of EGFP in dendritic cells transfected with in vitro transcribed mRNA or cellular total RNA extracted from EGFP expressing leukemia cells.

Takahashi M, Narita M, Ayres F, Satoh N, Abe T, Yanao T, Furukawa T, Toba K, Hirohashi T, Aizawa Y.

Med Oncol. 2003;20(4):335-48.

PMID:
14716029
31.

Maize mutants lacking chloroplast FtsY exhibit pleiotropic defects in the biogenesis of thylakoid membranes.

Asakura Y, Hirohashi T, Kikuchi S, Belcher S, Osborne E, Yano S, Terashima I, Barkan A, Nakai M.

Plant Cell. 2004 Jan;16(1):201-14. Epub 2003 Dec 19.

32.

Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA.

Osman Y, Narita M, Ayres F, Takahashi M, Alldawi L, Tatsuo F, Toba K, Hirohashi T, Aizawa Y.

Cytotherapy. 2003;5(2):161-8.

PMID:
12745578
33.
34.

Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3.

Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y.

Pharm Res. 2002 Jan;19(1):34-41.

PMID:
11837698
35.
36.

Intradiscal pressure after intradiscal injection of hypertonic saline: an experimental study.

Sato K, Nagata K, Ariyoshi M, Hirohashi T, Inoue A.

Eur Spine J. 2000 Jun;9(3):213-7.

37.

Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2.

Morikawa A, Goto Y, Suzuki H, Hirohashi T, Sugiyama Y.

Pharm Res. 2000 May;17(5):546-52.

PMID:
10888306
38.
39.
40.

Characterization of inducible nature of MRP3 in rat liver.

Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y.

Am J Physiol Gastrointest Liver Physiol. 2000 Mar;278(3):G438-46.

41.

ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3).

Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y.

J Biol Chem. 2000 Jan 28;275(4):2905-10.

42.
43.

Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2).

Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, Sugiyama Y.

J Pharmacol Exp Ther. 2000 Jan;292(1):265-70.

PMID:
10604957
44.

Chloroplast chaperonins: evidence for heterogeneous assembly of alpha and beta Cpn60 polypeptides into a chaperonin oligomer.

Nishio K, Hirohashi T, Nakai M.

Biochem Biophys Res Commun. 1999 Dec 20;266(2):584-7.

PMID:
10600546
45.

Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3).

Hirohashi T, Suzuki H, Sugiyama Y.

J Biol Chem. 1999 May 21;274(21):15181-5.

46.
47.

cDNA sequence and overexpression of chloroplast chaperonin 21 from Arabidopsis thaliana.

Hirohashi T, Nishio K, Nakai M.

Biochim Biophys Acta. 1999 Jan 11;1429(2):512-5.

PMID:
9989238
48.

cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3).

Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y.

FEBS Lett. 1998 Aug 14;433(1-2):149-52.

49.

Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.

Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, Sugiyama Y.

Mol Pharmacol. 1998 Jun;53(6):1068-75.

PMID:
9614210
50.

Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver.

Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, Sugiyama Y.

J Biol Chem. 1998 Jan 16;273(3):1684-8.

Supplemental Content

Loading ...
Support Center